Related Experiment Video
Updated: Feb 27, 2026
07:49
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
12.0K
Drug delivery devices for retinal diseases.
Hirokazu Kaji1, Nobuhiro Nagai2, Matsuhiko Nishizawa1
1Department of Finemechanics, Graduate School of Engineering, Tohoku University, 6-6-01 Aramaki, Aoba-ku, Sendai 980-8579, Japan.
Advanced Drug Delivery Reviews
|July 11, 2017
Summary
Implant devices offer a less invasive way to treat retinal degenerative diseases, overcoming barriers that limit traditional drug delivery methods. Future research focuses on enhancing these devices for better treatment outcomes.
Area of Science:
- Ophthalmology
- Biomedical Engineering
- Drug Delivery Systems
Background:
- Retinal degenerative diseases cause significant irreversible blindness globally.
- Intravitreal injections, while direct, are invasive and carry risks.
- Anatomical and physiological barriers challenge posterior eye drug delivery.
Purpose of the Study:
- To review current implant device-based therapies for retinal degenerative diseases.
- To discuss future directions and challenges in device-based retinal treatments.
Main Methods:
- Literature review of existing implant devices for posterior segment drug delivery.
- Analysis of anatomical and physiological challenges in ocular drug delivery.
- Discussion of future trends and unresolved issues in device development.
Main Results:
- Implant devices represent a promising alternative to intravitreal injections.
- Current devices aim to overcome ocular barriers for sustained drug release.
- Significant challenges remain in optimizing device efficacy and safety.
Conclusions:
- Device-based therapies are crucial for managing retinal degenerative diseases.
- Further innovation is needed to address challenges in design and application.
- Future research should focus on improving implantable drug delivery systems for enhanced patient outcomes.
Related Concept Videos
01:23Ophthalmic Drug Delivery Systems
97
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
97
01:22Drug Delivery: Miscellaneous Routes
885
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
885
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
57
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
57
01:27Drug Delivery Systems: Different Types
92
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
92
01:19Modified-Release Drug Delivery Systems: Overview
63
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
63
01:21Intrauterine Drug Delivery Systems
57
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
57